VBL Adds Progression Free Survival as Second Primary Endpoint in Ovarian Cancer Study

 

• Second primary endpoint added following discussion with the U.S. Food and Drug Administration
• Successfully meeting either PFS or OS primary endpoints expected to be sufficient for submitting a BLA for potential full FDA approval
• PFS endpoint readout expected in 2022; BLA submission could be possible one year earlier than previously projected with OS endpoint alone
• Clinical trial amendment reported in an OVAL Clinical Trial in Progress poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

https://www.globenewswire.com/news-release/2021/06/03/2241149/0/en/VBL-Therapeutics-Announces-Addition-of-Progression-Free-Survival-as-a-Second-Primary-Endpoint-in-OVAL-a-Phase-3-Registration-Enabling-Study-of-VB-111-in-Ovarian-Cancer.html